Anavex Life Sciences Corp. (AVXL) — Financial statements
Income statement, balance sheet, and cash flow for Anavex Life Sciences Corp. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 38↓10.1% | 42↓4.3% | 44↑15.3% | 38↑15.0% | 33 | |
| General & Administrative Expenses | 14↑25.2% | 11↓8.4% | 12↓7.8% | 13↑44.9% | 9 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 14↑25.2% | 11↓8.4% | 12↓7.8% | 13↑44.9% | 9 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 51↓2.8% | 53↓5.2% | 56↑9.4% | 51↑21.4% | 42 | |
| Total Costs & Expenses | 51↓2.8% | 53↓5.2% | 56↑9.4% | 51↑21.4% | 42 | |
| Operating Results | ||||||
| Operating Income | -51↑2.8% | -53↑5.2% | -56↓9.4% | -51↓21.4% | -42 | |
| Depreciation & Amortization | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EBITDA | -46↓7.8% | -43↑7.6% | -47↑2.3% | -48↓26.5% | -38 | |
| EBIT | -46↓7.8% | -43↑7.6% | -47↑2.3% | -48↓26.5% | -38 | |
| Interest & Other Income | ||||||
| Net Interest Income | 5↓36.1% | 7↑31.8% | 6↑486.6% | 0.95↑3542.3% | 0.03 | |
| Interest Income | 5↓36.1% | 7↑12.3% | 7↑588.4% | 0.95↑3542.3% | 0.03 | |
| Interest Expense | 0.00 | 0.00↓100.0% | 0.96 | 0.00 | 0.00 | |
| Non-Operating Income | -5↑49.1% | -10↓7.1% | -9↓174.0% | -3↑22.8% | -4 | |
| Other Income / Expenses | 5↓49.1% | 10↑19.6% | 8↑145.3% | 3↓22.8% | 4 | |
| Income Before Tax | -46↓7.8% | -43↑9.5% | -48↑0.2% | -48↓26.5% | -38 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00↓100.0% | 0.36↑33.6% | 0.27 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -46↓7.8% | -43↑9.5% | -48↑1.0% | -48↓26.6% | -38 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -46↓7.8% | -43↑9.5% | -48↑1.0% | -48↓26.6% | -38 | |
| Bottom-Line Net Income | -46↓7.8% | -43↑9.5% | -48↑1.0% | -48↓26.6% | -38 | |
| EPS (Basic) | -0.54↓3.8% | -0.52↑13.3% | -0.60↑3.2% | -0.62↓14.8% | -0.54 | |
| EPS (Diluted) | -0.54↓3.8% | -0.52↑13.3% | -0.60↑3.2% | -0.62↓14.8% | -0.54 | |
| Weighted Average Shares | 85↑2.2% | 83↑4.6% | 80↑3.7% | 77↑10.2% | 70 | |
| Weighted Average Diluted Shares | 85↑2.2% | 83↑4.6% | 80↑3.7% | 77↑10.2% | 70 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.